Why corporate event data matters & how it moves the market.

IROs Widen What’s on Their Radar with Corporate Event Intelligence

An IRO’s job is to provide bi-directional visibility. They give their management teams visibility into what the financial community thinks about how their companies are being run both individually and as compared to others in their sectors. Ultimately it is those perceptions that affect their stock prices. Conversely, the IRO has groups to service – shareholders, analysts and other financial constituents – for whom they provide visibility into their companies’ strategies, operations and performance.

Read More »

Corporate Events Data — Time for a Closer Look

Publicly traded companies are scrutinized more than ever today. Information about them is dissected and fed into investors’ models and trading strategies the instant it becomes available. When signals are detected, they trigger actions, often in microseconds. So having better information sooner is the name of the game.

Read More »

Digital Turnaround – The Growing Importance of Face-to-Face Investor Conferences

A recent article from CNBC shows that asset managers and hedge funds are becoming increasingly reluctant to pay for analyst research reports that they once relied on so heavily. In fact, data shows a 25% decrease from client spend on reports compared to a year earlier.  While the importance and need for in-depth research and insight is by no means diminishing, the means in which traders are consuming and obtaining analyst intelligence is changing in a somewhat surprising way.

Read More »

Why Investors and Traders Need to Track PDUFA Dates

With the strong comeback of the biotech sector in 2017, now is as good a time as any to consider the corporate event data that can affect volatility. Although event data can range from FDA drug approval dates and FDA Advisory Committee meetings to investor conferences and analyst days, in this post, I’d like to focus on FDA drug approval dates.

Read More »

How Is Wall Street Horizon Better? Uncensored Opinions from our Undisclosed Clients

iStock-841941260 (1).jpgIn nearly every meeting I have with prospects, they ask the same question: 

“How is Wall Street Horizon’s corporate events data better than what we get with our ‘big box’ data terminal?”

Rather than hear from me, answers straight from our clients are far more impactful. After all, they’re the ones paying to use our data every day to inform their models, sharpen their strategies, and to gain an edge that helps them make money or avoid losing it.

Read More »

Corporate ‘Body Language’ and How to Capitalize on It

body_language_bookcover.jpgAlso published in Traders Magazine

We all know what body language is. The classic book Body Language by Julius Fast popularized the topic in 1970 and it has since sold over three million copies.

We all use non-verbal forms of communication with our posture, gestures and facial expressions. Sometimes it’s used consciously and purposefully, such as when a detective interrogates a suspect.  But most often, it’s done subconsciously, like when a hiring manager is assessing a job candidate.

Read More »

Early 2016 Outlook Report – Upcoming Drug Catalysts

For the past couple weeks I’ve been writing on this blog and in our newsletter about FDA drug approval dates (PDUFA dates) and the impact that these catalysts can have on a drug manufacturer’s stock price.  This week I thought I would let our partner Informa do most of the talking.  And why not, considering their opinions successfully predicted 75% of the catalyst outcomes that occurred in Q4 2015!

Read More »